Geron Expands Sales Force by 20%, Targets RYTELO Impact by Year-End and EU Launch Progress

Management Highlights

Dawn Carter Bir, Interim President and CEO of Geron Corporation, emphasized the appointment of Harout Semerjian as the company's new President and CEO. She highlighted his experience in hematology and oncology, expressing confidence in his ability to drive value for shareholders. The company remains focused on the U.S. commercialization of RYTELO, with Bir stating, “We are executing with precision across our enhanced and aligned commercial and medical affairs strategies established this past quarter. We see that they're beginning to translate into measurable results and believe that we have implemented the right strategies that will drive continued commercial success.”

Bir also reported that Q2 RYTELO net revenues reached $49 million, marking a 24% increase from the first quarter. This growth was partly driven by increased demand from new patient starts. She noted the expansion of the commercial and medical affairs teams, with the sales force and customer-facing roles growing by over 20%, and the medical affairs organization doubling in size. These changes, she said, position the company to achieve the key opinion leader (KOL) support needed for RYTELO’s unique mechanism of action.

James Ziegler, Chief Commercial Officer, added that demand growth in the second quarter was 17% higher than in the first quarter. He credited the cross-functional team’s execution and noted that almost all of the new commercial hires were now trained and deployed in the field.

Michelle J. Robertson, CFO, reported that as of June 30, 2025, the company had approximately $433 million in cash and marketable securities, down from $503 million at the end of 2024. Total net product revenue for the three months ended June 30, 2025, was $49 million. She confirmed that for fiscal year 2025, the company still expects total operating expenses to be between $270 million and $285 million.

Outlook and Strategic Focus

Management reiterated its FY2025 operating expense guidance of $270 million to $285 million, which includes continued investment in RYTELO commercialization and preparations for an EU launch in 2026. The company expects the impact of its expanded sales and medical affairs teams to be felt by year-end and is maintaining financial discipline for the EU launch, pending favorable pricing and reimbursement.

The IMpactMF Phase III trial in relapsed/refractory myelofibrosis is expected to complete enrollment by year-end, with an interim analysis projected for the second half of 2026 and final analysis in the second half of 2028.

Financial Results

Geron reported $49 million in total net product revenue for Q2 2025, up from $39.4 million in Q1 2025. Cash and marketable securities stood at $433 million at the end of the quarter. Research and development expenses were $22 million for the quarter, a decrease from $31 million in the same period last year, attributed to lower clinical trial costs and capitalized manufacturing expenses post-FDA approval. Selling, general, and administrative expenses were $39 million, roughly unchanged from the previous year.

Gross to net remained in the mid-teens percent from Q1 to Q2, and inventory levels were within the target range of 2 to 4 weeks.

Q&A Insights

Analysts asked a variety of questions about RYTELO’s performance, including the number of active patients and the impact of new messaging on demand. James Ziegler mentioned that while exact figures are not disclosed, the minimum threshold for new patient starts is estimated to be over 600, with about 30% in first and second lines.

Peter Richard Lawson asked about the sustainability of the 17% demand growth and KOL engagement strategies. Ziegler discussed continued investment in KOL engagement and peer-to-peer initiatives, while Joseph Emile Eid described tailored KOL interactions to inform strategy and clinical development.

Faisal Ali Khurshid inquired about the effectiveness of new strategies and duration of therapy trends. Bir and Ziegler pointed to increased awareness, prescribing comfort, and KOL engagement as key drivers, with Ziegler noting that duration of therapy is expected to improve as use moves into earlier lines.

Stephen Douglas Willey asked about early Q3 demand trends and myelofibrosis trial enrollment. Ziegler expressed cautious optimism for continued demand, while Eid confirmed strong enrollment, expecting completion by year-end.

Gil Joseph Blum asked about physician types prescribing RYTELO in earlier lines and reasons for non-retention. Ziegler and Eid cited community and academic prescribers with increasing awareness, and Ziegler attributed some discontinuations to cytopenias, emphasizing ongoing education efforts.

Emily Claudia Bodnar questioned expectations for first/second line usage split and prior therapies used. Ziegler declined to provide specific guidance but reiterated the goal for appropriate first-line and ESA-relapsed usage.

Gregory Allen Harrison asked about the EU commercialization strategy. Ziegler stressed the priority of securing strong reimbursement and confirmed engagement with potential partners, maintaining financial discipline.

Corinne Johnson requested historical context for first/second line usage metrics and leading indicators for sales force recalibration. Ziegler referenced consistent use of IQVIA claims data and detailed internal performance metrics.

Sentiment Analysis

Analysts focused on patient uptake, sustainability of demand growth, and execution of commercial strategies, displaying a generally positive but probing tone as they sought clarity on new patient data and the impact of strategic changes.

Management remained confident throughout prepared remarks and Q&A, with Ziegler expressing enthusiasm: “...all credit to our customer-facing teams, the existing team, executing the existing plan of action delivered the results that we just reported in the second quarter.” The tone was consistently positive and forward-looking, similar to the previous quarter but with increased confidence supported by improved results and the appointment of a new CEO.

Compared to last quarter, both analysts and management demonstrated greater optimism, attributed to tangible sales growth and progress in execution.

Quarter-over-Quarter Comparison

The current quarter saw a strong rebound in RYTELO revenues and demand, up 24% and 17% respectively over Q1. This contrasts with the previous quarter, where revenues declined due to inventory drawdown and demand was described as flat.

Strategic focus has shifted from addressing underperformance and implementing corrective measures to expanding and executing a refined commercial plan, particularly through sales force growth and enhanced KOL engagement.

Analysts’ questions shifted from inventory and launch challenges to sustainability of momentum, physician behavior, and execution of expansion strategies.

Management’s tone evolved from defensive and corrective to confident and proactive, reflecting improved commercial performance and organizational stability following the CEO appointment.

Key metrics showed positive movement: revenue growth, increased site utilization, higher payer access (90% vs. 85%), and expansion of sales and medical teams.

Risks and Concerns

Management highlighted the need to maintain and increase RYTELO brand awareness, prescribing clarity, and KOL advocacy to ensure continued uptake and growth.

Some level of disruption is anticipated as the sales force and territories expand, but teams are working to minimize impact.

Product discontinuations, particularly due to cytopenias, remain a concern, with educational initiatives underway to address physician management and retention.

EU commercialization is contingent on achieving favorable reimbursement rates, and the company is maintaining financial discipline to avoid premature investment.

Final Takeaway

Geron management underscored that the second quarter reflected early success from refined commercial and medical strategies, with RYTELO revenue and demand showing significant growth. The expansion of sales and medical affairs teams, strengthened KOL engagement, and a disciplined approach to EU launch preparations all contribute to an optimistic outlook. With a new CEO at the helm, the company signals confidence in sustaining commercial momentum and achieving long-term objectives for RYTELO and its broader pipeline.